PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

News

PCSK9 emerges as a key determinant of site of organ metastasis in pancreatic cancer Inclisiran shown to be effective in adolescents with HoFH Study lays ground work for saffron as natural PCSK9 inhibitor PCSK9 inhibitors could reduce cardiac remodelling following MI PCSK9 inhibitors do not increase bleeding events after PCI Older ASCVD patients benefit from LDL-C lowering with evolocumab

Events

Posted on 3 December 2024 |

European Society of Cardiology Congress 2025 with World Congress of Cardiology
Event start date: 29 Aug 2025
Madrid, Spain, and online

American Heart Association Scientific Sessions 2025
Event start date: 8 Nov 2025
New Orleans, USA

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.